Anti-CTLA-4 nanobodies offer promising strategy to prevent colitis in cancer immunotherapy
Date | 4th, Jan 2024 |
---|---|
Source | News Medical - Scientific News Websites |
DESCRIPTION
Microbiota-reactive T cells trigger colitis in mice harboring the microbiota of wild-caught mice following CTLA-4 blockade, according to a new study that reveals a major mechanism by which anti-CTLA-4 antibodies induce inflammatory toxicities during antitumor immune checkpoint inhibitor therapies.